Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03593317

Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD — BRAVE  

Arrhythmogenic Right Ventricular Dysplasia Clinical Trial

Official title:
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD: a Double-blind Multicentre Prospective Randomized Study.

Clinical Trial Summary

Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV). These infiltrations lead to cardiac electrical instability and ventricular arrhythmia. Current treatment for ARVD is empirical and essentially based on treatment of arrhythmia. Thus, there is no validated treatment that will prevent the deterioration of the RV function in patients with ARVD. The investigator's hypothesis is that the use of anti-fibrotic medications will prevent or at least reduce the deterioration of the RV function. The aim of this project is to evaluate the effect of spironolactone, a Potassium-sparing diuretic on ventricular myocardial remodeling and on arrhythmia burden in patients with ARVD. The trial is a double-blind parallel multicenter prospective randomized phase II drug study. Patients will be randomized in the two groups: spironolactone or placebo. 13 centers in France will enroll the 120 patients (60 per group). Patients will be followed for 3 years (6 months, 1 year and 3 years) with all examinations (ECG, HA ECG, 24-hour Holter, trans-thoraciqc echocardiography (TTE), biological analyses) according to standard of care. A decrease in right and/or left ventricular deterioration and in arrhythmia burden are expected in ARVD patients treated with spironolactone. This reduction will improve the quality of life of patients and will reduce the number of hospitalizations and the risk of terminal heart failure.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Arrhythmogenic Right Ventricular Dysplasia
Clinical Trial Details
NCT number NCT03593317
Study type Interventional
Source Hospices Civils de Lyon
Contact Roucher Aude, PhD
Phone 426739447
Email aude.roucher@chu-lyon.fr
Status Not yet recruiting
Phase Phase 2
Start date March 2024
Completion date March 2028
View Details
See also
  Status Clinical Trial Phase
Completed NCT00999947 - Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy N/A
Completed NCT00024505 - Multidisciplinary Study of Right Ventricular Dysplasia N/A
Completed NCT03177018 - DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia N/A
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Active, not recruiting NCT04257994 - Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders
Recruiting NCT06275893 - IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy Phase 1/Phase 2
Recruiting NCT05521451 - Clinical Cohort Study - TRUST
Recruiting NCT03049254 - Mayo AVC Registry and Biobank
Recruiting NCT05209776 - Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy N/A
Recruiting NCT04712136 - Healthy-related Quality of Life and Physical Activity of Children With Cardiac Malformations N/A
Active, not recruiting NCT04895540 - South Asian Arrhythmogenic Cardiomyopathy Registry